Elucid is a medical technology company based in Boston, founded in 2013. The firm develops AI-powered software for cardiovascular imaging, with a focus on atherosclerosis analysis. Its team comprises 51 employees working across the technical domains of artificial intelligence, medical imaging, and image analysis.
The company's principal product, PlaqueIQ™, is described as the first and only FDA-cleared, non-invasive plaque analysis software that has been validated against ground-truth histology. The software enables objective quantification and classification of plaque morphology, including lipid-rich necrotic core, calcified, and non-calcified plaque types.
Elucid operates at the intersection of healthcare and cardiovascular disease, applying machine learning techniques to help clinicians characterise arterial plaque through standard imaging workflows.
